Manipulation of transgenes by site-specific recombination: use of Cre recombinase.
Sauer
B
B
Biotechnology, Du Pont Merck Pharmaceutical Company, Wilmington, Delaware 19880.
D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D016466:CHO Cells; D006224:Cricetinae; D004247:DNA / Q000378:metabolism; D004254:DNA Nucleotidyltransferases / Q000378:metabolism*; D005786:Gene Expression Regulation; D005822:Genetic Vectors; D019426:Integrases; D019868:Kanamycin Kinase; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000096:biosynthesis / Q000235:genetics; D010957:Plasmids; D011995:Recombination, Genetic; D015183:Restriction Mapping; D014162:Transfection; D014764:Viral Proteins; D015053:Zygote / Q000378:metabolism
D014764:Viral Proteins; D004247:DNA; D017853:Phosphotransferases (Alcohol Group Acceptor); D019868:Kanamycin Kinase; C045073:Cre recombinase; D004254:DNA Nucleotidyltransferases; D019426:Integrases